News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlycoMimetics, Inc. (GLYC) Presents Data On Its E-Selectin Antagonist At American Association for Cancer Research Annual Meeting 2014


4/9/2014 8:09:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that three posters of preclinical research study data for its E-Selectin antagonist (GMI-1271) were highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2014. GlycoMimetics is initially exploring the clinical use of the drug to treat acute myeloid leukemia (AML). The company plans to initiate a Phase 1 trial of GMI-1271 in healthy volunteers during the second quarter of 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES